Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: October 29, 2007
Last updated: December 18, 2015
Last verified: December 2015

Vicriviroc (vye-kri-VYE-rock) is an investigational drug (not yet approved by Government Regulatory Authorities for commercial use) that belongs to a new class of drugs, called CCR5 receptor blockers. This group of drugs blocks one of the ways HIV enters T-cells (the cells that fight infection). Previous smaller studies in HIV treatment-experienced patients, have shown that vicriviroc is safe and effective. The purpose of this study is to investigate in subjects with detectable dual/mixed CCR5/CXCR4-tropic HIV whether vicriviroc when added to other appropriate HIV drugs can decrease the level of HIV (viral load) in the blood and that it is well tolerated.

This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study of vicriviroc maleate in HIV subjects infected with dual/mixed CCR5/CXCR4-tropic virus and who have documented resistance to at least 2 of the 3 antiretroviral drug classes (NRTI, NNRTI or PI) or at least 6 months experience with at least 2 of the following: one NRTI, one NNRTI, or one PI (excluding low-dose ritonavir) and failure on their current stable regimen. The study will compare the virologic benefit of adding vicriviroc to an optimized background regimen to a control group receiving placebo plus the new optimized background therapy. The optimized background regimen will be chosen by the investigator based on results of drug susceptibility tests performed at Screening, history of prior antiretroviral drug use by the patient, and drug toxicity. Primary efficacy analysis will be conducted when all subjects have completed 48 weeks of treatment. An interim analysis will be performed when all subjects have completed 24 weeks of treatment. Subjects who complete 48 weeks of treatment, or who discontinue early but are deemed eligible upon rescreening, will be offered participation in the open-label segment of the study, and will receive vicriviroc 30 mg once daily, if appropriate, until commercially available or until the sponsor terminates the clinical development of vicriviroc.

Condition Intervention Phase
HIV Infections
Acquired Immunodeficiency Syndrome
Drug: Vicriviroc
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Vicriviroc in Combination Treatment With an Optimized ART Regimen in Treatment-Experienced Subjects With R5/X4 HIV Infection (VICTOR-E2; Protocol No. P05057)

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Change from baseline in HIV RNA (log10 copies/mL) [ Time Frame: At Week 48 ]

Secondary Outcome Measures:
  • Change from baseline in CD4 count [ Time Frame: At Week 24 and Week 48 ]

Enrollment: 111
Study Start Date: September 2007
Study Completion Date: May 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Vicriviroc 30 mg QD
Drug: Vicriviroc
One tablet of vicriviroc 30 mg once daily
Placebo Comparator: 2
Drug: Placebo
One tablet of placebo once daily


Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must be at least 16 years of age (or minimal age that defines an adult as determined by local regulatory authorities or legal requirements), of either sex and of any race, with dual/mixed CCR5/CXCR4 tropic HIV infection.
  • Subjects must have treatment failure (defined by plasma HIV RNA [ribonucleic acid] >1000 copies/mL) on an existing regimen.
  • Subjects must be antiretroviral therapy (ART)-experienced and have documented genotypic and/or phenotypic resistance to at least one drug in 2 of the following 3 drug classes: nucleoside reverse transcriptase inhibitor (NRTI), nonnucleoside reverse transcriptase inhibitor (NNRTI), or protease inhibitor (PI)


  • Antiretroviral class experience for at least 6 months (sequential or cumulative) with at least two of the following:

    • one NRTI
    • one NNRTI
    • one PI (excluding low dose ritonavir).
  • In the opinion of the investigator, the best treatment regimen for the subject must be an optimized ART regimen consisting of >=3 drugs, the optimized regimen must contain at least 2 active drugs, one of which must be a ritonavir-boosted PI (>=100 mg ritonavir). With the exception of etravirine, NNRTIs may not be a component of the optimized regimen.

Exclusion Criteria:

  • Any condition likely to increase the risk of seizures.
  • CD4 count <100 cells/mm^3.
  • Current or prior history of malignancy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00551330     History of Changes
Other Study ID Numbers: P05057
Study First Received: October 29, 2007
Last Updated: December 18, 2015

Keywords provided by Merck Sharp & Dohme Corp.:
Treatment Experienced

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immune System Diseases
Slow Virus Diseases processed this record on April 28, 2017